Paper Details

  1. Home
  2. Paper Details

Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension.

Author: BakrisGeorge L, CaoCharlie, KupferStuart, RobertsAndrew, SicaDomenic, WeberMichael A, WhiteWilliam B

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

The study found that coadministration of azilsartan medoxomil with amlodipine was well tolerated and led to meaningful additional blood pressure (BP) reductions compared with placebo plus amlodipine.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: The aim of the study was to measure the effects on blood pressure (BP) of the angiotensin receptor blocker azilsartan medoxomil, in 40 and 80 mg doses, combined with 5 mg of the calcium channel blocker amlodipine and to compare these effects with placebo plus amlodipine 5 mg. METHODS: Th...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3966914/

データ提供：米国国立医学図書館（NLM）

Azilsartan Medoxomil: A Promising Addition to Hypertension Management

This study investigated the effectiveness of azilsartan medoxomil, an angiotensin receptor blocker, in combination with amlodipine, a calcium channel blocker, for managing stage 2 hypertension. The research involved a randomized, controlled, double-blind trial comparing different doses of azilsartan medoxomil with placebo plus amlodipine in patients with hypertension. The study's focus on 24-hour ambulatory blood pressure monitoring provides a comprehensive assessment of the drug's effects over time.

A Significant Improvement in Blood Pressure Control

The results demonstrated that both doses of azilsartan medoxomil, when combined with amlodipine, significantly reduced 24-hour systolic and diastolic blood pressure compared to placebo plus amlodipine. This finding highlights the potential of azilsartan medoxomil as a valuable addition to the treatment regimen for hypertension, offering a greater reduction in blood pressure compared to amlodipine alone.

A Well-Tolerated Combination Therapy

The study also found that both combination therapies were well tolerated, with minimal side effects. The incidence of edema or fluid retention was significantly lower in the combination groups compared to placebo plus amlodipine, suggesting a more favorable safety profile for these treatments. The findings provide evidence supporting the use of azilsartan medoxomil in combination with amlodipine as a safe and effective option for managing stage 2 hypertension.

Dr.Camel's Conclusion

This study, like a camel carrying a precious cargo of blood pressure-lowering medication, offers a promising new approach to managing hypertension. The combination of azilsartan medoxomil with amlodipine demonstrates a significant improvement in blood pressure control compared to amlodipine alone, offering a more effective and well-tolerated treatment option for patients with stage 2 hypertension.

Date :
  1. Date Completed 2014-11-03
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

24445723

DOI: Digital Object Identifier

PMC3966914

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.